AAAAAA

   
Results: 1-8 |
Results: 8
RESPONSE-ORIENTED INDIVIDUALIZED INDUCTION THERAPY WITH 6 DRUGS FOLLOWED BY 4 COURSES OF INTENSIVE CONSOLIDATION, 1 YEAR MAINTENANCE AND INTENSIFICATION THERAPY - THE ALL90 STUDY OF THE JAPAN ADULT LEUKEMIA STUDY-GROUP
Authors: UEDA T MIYAWAKI S ASOU N KURAISHI Y HIRAOKA A KURIYAMA K MINAMI S OHSHIMA T INO T TAMURA J KANAMARU A NISHIKAWA K TANIMOTO M OH H SAITO K NAGATA K NAOE T YAMADA O URASAKI Y SAKURA T OHNO R
Citation: T. Ueda et al., RESPONSE-ORIENTED INDIVIDUALIZED INDUCTION THERAPY WITH 6 DRUGS FOLLOWED BY 4 COURSES OF INTENSIVE CONSOLIDATION, 1 YEAR MAINTENANCE AND INTENSIFICATION THERAPY - THE ALL90 STUDY OF THE JAPAN ADULT LEUKEMIA STUDY-GROUP, International journal of hematology, 68(3), 1998, pp. 279-289
IDARUBICIN AND IDARUBICINOL ARE LESS AFFECTED BY TOPOISOMERASE II-RELATED MULTIDRUG-RESISTANCE THAN IS DAUNORUBICIN
Authors: FUKUSHIMA T INOUE H TAKEMURA H KISHI S YAMAUCHI T INAI K NAKAYAMA T IMAMURA S URASAKI Y NAKAMURA T UEDA T
Citation: T. Fukushima et al., IDARUBICIN AND IDARUBICINOL ARE LESS AFFECTED BY TOPOISOMERASE II-RELATED MULTIDRUG-RESISTANCE THAN IS DAUNORUBICIN, Leukemia research, 22(7), 1998, pp. 625-629
INTRACELLULAR ARA-CTP CONTENT, AN ACTIVE METABOLITE OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE (ARA-C) IN LEUKEMIC-CELLS FROM PATIENTS RECEIVING (LOW-DOSE) ARA-C THERAPY MEASURED BY THE NEWLY ESTABLISHED SENSITIVE ASSAY
Authors: YAMAUCHI T KISHI S KAWAI Y URASAKI Y FUKUSHIMA T IWASAKI H TSUTANI H WANO Y NAKAMURA T GOTO N MASADA M UEDA T
Citation: T. Yamauchi et al., INTRACELLULAR ARA-CTP CONTENT, AN ACTIVE METABOLITE OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE (ARA-C) IN LEUKEMIC-CELLS FROM PATIENTS RECEIVING (LOW-DOSE) ARA-C THERAPY MEASURED BY THE NEWLY ESTABLISHED SENSITIVE ASSAY, Blood, 90(10), 1997, pp. 3662-3662
SUPERIOR CYTOTOXIC POTENCY OF MITOXANTRONE IN INTERACTION WITH DNA - COMPARISON WITH THAT OF DAUNORUBICIN
Authors: FUKUSHIMA T KAWAI Y NAKAYAMA T YAMAUCHI T YOSHIDA A URASAKI Y IMAMURA S KAMIYA KI TSUTANI H UEDA T NAKAMURA T
Citation: T. Fukushima et al., SUPERIOR CYTOTOXIC POTENCY OF MITOXANTRONE IN INTERACTION WITH DNA - COMPARISON WITH THAT OF DAUNORUBICIN, Oncology research, 8(2), 1996, pp. 95-100
CIRCUMVENTION OF DAUNORUBICIN RESISTANCE BY A NEW TAMOXIFEN DERIVATIVE, TOREMIFENE, IN MULTIDRUG-RESISTANT CELL-LINE
Authors: URASAKI Y UEDA T NAKAMURA T
Citation: Y. Urasaki et al., CIRCUMVENTION OF DAUNORUBICIN RESISTANCE BY A NEW TAMOXIFEN DERIVATIVE, TOREMIFENE, IN MULTIDRUG-RESISTANT CELL-LINE, Japanese journal of cancer research, 85(6), 1994, pp. 659-664
PHARMACOKINETIC AND CLINICAL PILOT-STUDY OF HIGH-DOSE INTERMITTENT UBENIMEX TREATMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
Authors: UEDA T TOHYAMA K WANO Y TSUTANI H FUKUSHIMA T IWASAKI H URASAKI Y GOTOH N KIMURA S OKUMURA E KAGAWA D NAKAMURA T
Citation: T. Ueda et al., PHARMACOKINETIC AND CLINICAL PILOT-STUDY OF HIGH-DOSE INTERMITTENT UBENIMEX TREATMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, Anticancer research, 14(5B), 1994, pp. 2093-2097
INFLUENCE OF IDARUBICINOL ON THE ANTILEUKEMIC EFFECT OF IDARUBICIN
Authors: FUKUSHIMA T KAWAI Y URASAKI Y YOSHIDA A UEDA T NAKAMURA T
Citation: T. Fukushima et al., INFLUENCE OF IDARUBICINOL ON THE ANTILEUKEMIC EFFECT OF IDARUBICIN, Leukemia research, 18(12), 1994, pp. 943-947
CLINICAL-PHARMACOLOGY OF TA-D-ARABINOFURANOSYLCYTOSINE-5'-STEARYLPHOSPHATE, AN ORALLY-ADMINISTERED LONG-ACTING DERIVATIVE OF LOW-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE
Authors: UEDA T KAMIYA K URASAKI Y WATAYA S KAWAI Y TSUTANI H SUGIYAMA M NAKAMURA T
Citation: T. Ueda et al., CLINICAL-PHARMACOLOGY OF TA-D-ARABINOFURANOSYLCYTOSINE-5'-STEARYLPHOSPHATE, AN ORALLY-ADMINISTERED LONG-ACTING DERIVATIVE OF LOW-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE, Cancer research, 54(1), 1994, pp. 109-113
Risultati: 1-8 |